La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Precigen a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Precigen..

Precigen (NASDAQ:PGEN) Azioni, Catena delle Opzioni

PRECIGEN INC

Precigen

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Overweight and lowers the price target from $755 to $754.

News

Price Target

Analyst Ratings

REGN

Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $754

Barclays analyst Benjamin Budish maintains BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) with a Overweight and raises the price target from $990 to $1220.

Barclays Maintains Overweight on BlackRock, Raises Price Target to $1220

Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Overweight and raises the price target from $80 to $81.

LEGN

Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $81

Barclays analyst Nicholas Campanella maintains Atmos Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATO#NYSE">ATO</a>) with a Equal-Weight and lowers the price target from $156 to $153.

Barclays Maintains Equal-Weight on Atmos Energy, Lowers Price Target to $153

XRP's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) has broken above $2.39 for the first time since May 23, buoyed by growing whale accumulation and bullish momentum around Ripple's ecosystem. 
Market watchers now see signs of <a href="https://www.benzinga.com/money/ripple-xrp-price-prediction">an imminent breakout.</a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Ticker</td>
<td>Price</td>
<td>Market Cap</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>XRP</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.44</td>
<td>&nbsp;$144.4 billion</td>
<td>+7.8%</td>
</tr>
<tr>
<td>Bitcoin</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$111,368.12</td>
<td>&nbsp;$2.2 trillion</td>
<td>+1.6%&nbsp;</td>
</tr>
<tr>
<td>Ethereum</td>
<td>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,771.92</td>
<td>&nbsp;$335.1 billion</td>
<td>+7.4%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Cryptoinsightuk <a href="https://x.com/Cryptoinsightuk/status/1943233384819425509">noted</a> that XRP has cleared a key resistance level and is now holding it as hourly support. 
While yesterday's close hinted at bullish continuation, he says a strong close today would confirm a full-blown rally. Similar breakouts in the past have led to explosive moves, signaling what he calls potential "fireworks ahead."
Oscar Ramos, <a href="https://x.com/thecryptobasic/status/1943298136878772542">quoted </a>by Crypto Basic, is urging investors to go &#8220;all-in&#8221; on XRP, calling it a &#8220;must-have&#8221; in bullish portfolios. With Bitcoin hitting new highs at $112,000, altcoins like XRP are following with renewed strength. Ripple's progress with its RLUSD stablecoin and utility expansion is helping drive the sentiment shift.
Statistics: Santiment <a href="https://x.com/santimentfeed/status/1943017401009713342">data</a> shows XRP has reached a 7-week high, surpassing $2.39 for the first time since May 23. 
Whale activity is increasing, with 2,742 wallets now holding at least 1 million XRP, just one short of the all-time high. These large holders now control 47.32 billion XRP, signaling strong confidence in the asset's future.
Coinglass data shows XRP open interest increased 3.9% in a single day while derivatives trading volume expanded by 20.3%. 
Short liquidations of $7.97 million in the past 24 hours, continue to rise for the second consecutive day, implying traders forced to close their positions in the wake of XRP's rally.
Community News: Ripple <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46323539/xrp-boosted-4-by-ripples-stablecoin-partnership-with-bny-mellon">announced</a> that BNY, America's oldest running bank, will act as primary custodian for reserves backing its RLUSD stablecoin. The move aims to accelerate institutional trust and adoption.
Ripple is also actively pursuing a national bank charter and Federal Reserve master account to further legitimize RLUSD, which now <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46318111/xrp-eyes-2-40-as-ripples-rlusd-stablecoin-smashes-500m-market-cap">boasts </a>a more than $500 million market cap, making it the eighth-largest stablecoin after surpassing TrueUSD.
CEO Brad Garlinghouse reiterated that XRP's regulatory clarity is now well established, calling this a green light for broader adoption and use.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46327959/xrp-spikes-3-is-a-breakout-imminent">XRP Spikes 3%: Is A Breakout Imminent?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

XRP Breaks Above $2.40 For First Time Since May: How High Can It Go?

Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Overweight and raises the price target from $132 to $133.

BNTX

Morgan Stanley Maintains Overweight on BioNTech, Raises Price Target to $133

Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Overweight and raises the price target from $1133 to $1135.

Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1135

Barclays analyst Benjamin Budish maintains Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) with a Overweight and raises the price target from $182 to $200.

ARES

Barclays Maintains Overweight on Ares Management, Raises Price Target to $200

Morgan Stanley analyst Terence Flynn maintains United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Equal-Weight and lowers the price target from $348 to $328.

UTHR

Morgan Stanley Maintains Equal-Weight on United Therapeutics, Lowers Price Target to $328

Morgan Stanley analyst Betsy Graseck maintains Ally Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) with a Overweight and raises the price target from $39 to $47.

ALLY

Morgan Stanley Maintains Overweight on Ally Financial, Raises Price Target to $47

Barclays analyst Benjamin Budish maintains Apollo Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Overweight and raises the price target from $156 to $168.

Barclays Maintains Overweight on Apollo Asset Management, Raises Price Target to $168

Morgan Stanley analyst Betsy Graseck maintains American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) with a Equal-Weight and raises the price target from $250 to $311.

Morgan Stanley Maintains Equal-Weight on American Express, Raises Price Target to $311

Barclays analyst Eric Beaumont maintains American Water Works Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>) with a Underweight and lowers the price target from $138 to $128.

Barclays Maintains Underweight on American Water Works Co, Lowers Price Target to $128

Barclays analyst Brandon Oglenski maintains American Airlines Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) with a Equal-Weight and raises the price target from $11 to $12.

Barclays Maintains Equal-Weight on American Airlines Group, Raises Price Target to $12

<a href="https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_07102025_SNGX_Bautz.pdf" title="https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_07102025_SNGX_Bautz.pdf">https://scr.zacks.com/files/News/2025/Zacks_SCR_Research_07102025_SNGX_Bautz.pdf</a>

Trading Ideas

SNGX

Watching Soligenix; Zacks Small-Cap Research Gives Stock $35 Price Valuation

Barclays analyst Nicholas Campanella maintains Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) with a Equal-Weight and lowers the price target from $104 to $100.

Barclays Maintains Equal-Weight on Ameren, Lowers Price Target to $100

B of A Securities analyst Bryan Spillane reinstates Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Buy and announces $110 price target.

Initiation

B of A Securities Reinstates Buy on Estee Lauder Cos, Announces $110 Price Target

Gorilla Technology Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) shares plunged on Thursday, reversing a strong rally from the previous session that was driven by trader enthusiasm over the company&#8217;s <a target="_blank" href="https://www.gorilla-technology.com/" rel="noreferrer noopener">listing</a> as an NVIDIA Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) NVIDIA Solutions Partner on its website.
This designation suggests a deeper collaboration with NVIDIA, potentially giving Gorilla access to advanced AI tools and enhancing its market credibility. While no formal press release has been issued, the partnership has already sparked strong investor interest.
On July 3, Gorilla announced a $105 million <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46169804/gorilla-technology-grrr-stock-falls-after-105m-offering" rel="noreferrer noopener">registered direct offering</a>, anchored by a $100 million investment from a new institutional investor. An existing shareholder also increased its position. The company will issue 6 million ordinary shares at $17.50 per share, with proceeds allocated to support performance guarantees, bid bonds, project bids, acquisitions, and general working capital.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46007657/gorilla-technology-stock-surges-on-q1-earnings-as-momentum-builds" rel="noreferrer noopener">Gorilla Technology Stock Surges On Q1 Earnings As Momentum Builds</a>
Separately, Gorilla also announced a definitive agreement to <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46075366/gorilla-technology-grrr-stock-surges-on-agreement-to-acquire-thai-ai-firms" rel="noreferrer noopener">acquire</a> Thai tech firms CNS and CANS, aiming to expand its AI-powered customer engagement platform across Southeast Asia.
The acquisition adds a client base of more than 200 businesses and nationwide coverage across Thailand&#8217;s 77 provinces, creating new recurring revenue opportunities in the telecom, government, and enterprise sectors.
GRRR shares have fallen sharply, down about 52% from their 52-week high of $44.15 to recent lows near $21 in early July. Despite the pullback, the stock remains up approximately 16.4% year-to-date and trades within a wide 52-week range of $2.09 to $44.15.
Price Action: At the last check on Thursday, GRRR shares were trading lower by 14.63% to $20.71.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46342321/nvidia-microsoft-apple-smash-10-trillion-is-this-peak-tech" target="_blank" rel="noreferrer noopener">Nvidia, Microsoft, Apple Smash $10 Trillion—Is This Peak Tech?</a></li>
</ul>
Image via Shutterstock

Movers

GRRR

NVDA

Gorilla Technology Shares Plunge After Nvidia-Fueled Rally Reverses

Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) is poised to benefit from rising enterprise demand for AI infrastructure, according to Piper Sandler.
The Oracle Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/586e4055351b9b00018beeab/brent-bracelin">Analyst Brent Bracelin</a> upgraded the rating to Overweight, while raising the price target from $190 to $270.
The Oracle Thesis: The bullish AI infrastructure spending backdrop could "add another layer of growth to the outsized OpenAI-Stargate opportunity," Bracelin said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
The latest CIO survey indicates the emergence of "additional upside levers" for Oracle, he stated.
"Net spending intentions for CIOs on Oracle OCI shot up to 27% (versus 18% in the prior survey), hinting at a growing enterprise appetite on top of the existing OpenAI/Stargate agreement that is poised to support triple-digit backlog growth during F2026," the analyst wrote.
He raised the earnings estimates for fiscal 2026 and 2027 from $6.60 per share to $6.65 per share and from $7.91 per share to $8 per share, respectively.
ORCL Price Action: Shares of Oracle had risen by 0.22% to $235.83 at the time of publication on Thursday.
Read More: • <a href="https://www.benzinga.com/markets/tech/25/07/46336890/amazon-may-pour-billions-more-into-anthropic-as-13-8-billion-ai-bet-grows-report">Amazon May Pour Billions More Into Anthropic As $13.8 Billion AI Bet Grows: Report</a>
Photo: Rokas Tenys via Shutterstock

Analyst Color

Upgrades

Tech

ORCL

Oracle Stock Upgrade On AI Surge, OpenAI Deal Seen Fueling Growth

Barclays analyst Brandon Oglenski maintains Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) with a Overweight and raises the price target from $55 to $60.

Barclays Maintains Overweight on Alaska Air Gr, Raises Price Target to $60

Earnings

Press Releases

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Offerings

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Comments

Precigen

Precigen (PGEN) Opzioni

Precigen (NASDAQ:PGEN) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO